These results are in agreement with observations in previous case–control studies using serum16, 18, 19 and plasma.13 Overall, these findings support the possibility that NfL not only in CSF but also plasma, can serve as a promising biomarker for the diagnosis and monitoring of disease progression of ALS. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.